

			7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
Tokyo International Forum	Room 1	Hall C (4F)	O-24 Parkinsonism and Related disorders 3	Web Neuroscience Frontier Symposium 03 Co-evolution of imaging and fluid biomarkers toward stratification of neurological disorders	LS-27 Eisai Co.,Ltd. / Biogen Japan, Ltd.	Web PL-03 Plenary Lecture 03 Speaker : Yusuke Nakamura Chair : Tatsushi Toda	Web VPr Vice President Lecture Speaker : Takanori Yokota Chair : Hidehiro Mizusawa	Web Neuroscience Frontier Symposium 04 A new era of cell and gene therapy for neurological diseases									
	Room 2	Hall B7 (1) (7F)	O-25 Neuroimmunology 3	Web New Guideline 01 Key Points and How to Use the Guidelines for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders 2023	LS-28 UCB Japan Co. Ltd.			Web History Session The interesting history of neurology									
	Room 3	Hall B7 (2) (7F)	O-26 Cerebrovascular disease 4	Lecture Marathon LM-07 LM-08 Lecture Marathon 07 Lecture Marathon 08	LS-29 Mitsubishi Tanabe Pharma Cooperation			Lecture Marathon LM-09 LM-10 Lecture Marathon 09 Lecture Marathon 10									
	Room 4	Hall B5 (1) (5F)	O-27 Cerebrovascular disease 5	Symposium 26 The future of reperfusion therapy in acute stroke	LS-30 argenx Japan K.K. Medical Affairs			Symposium 33 Novel diagnostic modality in neuromuscular disorders									
	Room 5	Hall B5 (2) (5F)	O-28 Peripheral neuropathy 1	Symposium 27 Latest genetic causes of neuropathy	LS-31 Novartis Pharma			Symposium 34 Japanese national policy of medicine, research, and development promoted by neurologists									
	Room 6	Hall D7 (7F)	O-29 Motor neuron disease 1	Web Hot Topics 06 Understanding and intervening cerebellar ataxias	Web LS-32 Alexion Pharmaceuticals, Inc.			Web Symposium 35 Development of treatments for hereditary muscle diseases that Japan is leading									
	Room 7	Hall D5 (5F)	O-30 Neuroimmunology 4	Symposium 28 Hyperkinetic movement disorders: update	LS-33 Eli Lilly Japan K.K. / DAIICHI SANKYO Co. Ltd.			Symposium 36 Neurovascular Unit as a Novel Therapeutic Target of Neurological Diseases									
	Room 8	Hall D1 (1F)	O-31 Neurogenetics 3	WFN-AOAN Session World Health Organization intersectoral global action plan; global implications	LS-34 Bristol-Myers Squibb / Pfizer Japan Inc.			Hot Topics 07 Delineating migraine as a multi-faceted neurological disorder									
	Room 9	G701 (7F)	O-32 Neuroinfection 2	Symposium 29 The evidence and future initiative around hearing loss, a risk factor of dementia	LS-35 Alfresa Pharma Corporation			Symposium 37 Pathomechanisms and novel treatment against IgG4 autoimmune diseases									
	Room 10	G502 (5F)	O-33 Cognitive dysfunction, Neuroimaging, and Sleep disorders	Symposium 30 Integration and evolution of multi-professional support for intractable disease	LS-36 Kyowa Kirin Co., Ltd.			Symposium 38 Update on the evaluation and treatment for dysphagia in neurological diseases									
	Room 11	G402 (4F)	O-34 Neuromuscular junction disorders 3	Symposium 31 New Strategies for the Diagnosis and Treatment of Neurological Disorders Derived from Neuroplasticity Research	LS-37 Biogen Japan Ltd.												
	Room 12	G409 (4F)	O-35 Muscle diseases 2	Symposium 32 Best clinical practice algorithm for successful management of neuroinfectious diseases and autoimmune encephalitis	LS-38 ONO PHARMACEUTICAL CO., LTD.			International Education Course 03 Educational session dementia									
	Room 13	G602 (6F)	O-36 Neurorehabilitation, Headache, etc.		LS-39 The Japanese Council of Nuclear Neuroimaging / The Japanese Society of Nuclear Medicine / Nihon Medi-Physics Co., Ltd.												
	Room 14	G610 (6F)	O-37 Neuroscience		LS-40 GlaxoSmithKline K.K.												
	Room 15	G510 (5F)			LS-41 Pfizer Japan Inc.												
Poster Session / Exhibition	Hall Bldg.	Hall E (B2F)		00 Poster Preparation / Poster Viewing	00 Poster Viewing			15 Poster Presentation / Discussion	35 Poster Removal	45 Exhibition							